Efficacy of satralizumab therapy in the treatment of NMOSD - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Biuletyn Wydziału Farmaceutycznego Warszawskiego Uniwersytetu Medycznego Année : 2023

Efficacy of satralizumab therapy in the treatment of NMOSD

Résumé

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with the presence of autoantibodies to anti–aquaporin-4 (AQP4-IgG). Interleukin-6 plays a key role in the pathogenesis of this disorder. Satralizumab, a humanized monoclonal antibody, targets the interleukin-6 receptor thus affects the course of the disease. In Poland, satralizumab treatment has been offered free of charge by the public health service since November 2021. The results of SAkura studies demonstrate the long terms efficacy of satralizumab and provide evidence that satralizumab reduces the risk of relapse in patients with aquaporin-4-immunoglobulin G (IgG)–seropositive (AQP4-IgG+) NMOSD.

Mots clés

Dates et versions

hal-04564271 , version 1 (03-05-2024)

Licence

Paternité - Pas d'utilisation commerciale - Partage selon les Conditions Initiales

Identifiants

Citer

Małgorzata Krzyżanowska, Katarzyna Kozon, Jakub Olszewski, Andrzej Patyra. Efficacy of satralizumab therapy in the treatment of NMOSD. Biuletyn Wydziału Farmaceutycznego Warszawskiego Uniwersytetu Medycznego, 2023, 21 (3), pp.64 - 68. ⟨10.56782/pps.166⟩. ⟨hal-04564271⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More